Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5193233
Max Phase: Preclinical
Molecular Formula: C54H90N6O31
Molecular Weight: 1319.33
Associated Items:
ID: ALA5193233
Max Phase: Preclinical
Molecular Formula: C54H90N6O31
Molecular Weight: 1319.33
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H](OC2CCCCC2)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6NC(C)=O)[C@H](O)[C@H]5NC(C)=O)[C@H](O)[C@H]4NC(C)=O)[C@H](O)[C@H]3NC(C)=O)[C@H](O)[C@H]2NC(C)=O)[C@@H]1O
Standard InChI: InChI=1S/C54H90N6O31/c1-18(67)55-31-38(74)37(73)25(12-61)81-50(31)87-45-27(14-63)83-52(33(40(45)76)57-20(3)69)89-47-29(16-65)85-54(35(42(47)78)59-22(5)71)91-48-30(17-66)86-53(36(43(48)79)60-23(6)72)90-46-28(15-64)84-51(34(41(46)77)58-21(4)70)88-44-26(13-62)82-49(32(39(44)75)56-19(2)68)80-24-10-8-7-9-11-24/h24-54,61-66,73-79H,7-17H2,1-6H3,(H,55,67)(H,56,68)(H,57,69)(H,58,70)(H,59,71)(H,60,72)/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50+,51+,52+,53+,54+/m1/s1
Standard InChI Key: MYQHCKRTHGRGJZ-YGIVDECYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1319.33 | Molecular Weight (Monoisotopic): 1318.5651 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zhang Y, Liang X, Bao X, Xiao W, Chen G.. (2022) Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective., 235 [PMID:35307617] [10.1016/j.ejmech.2022.114291] |
Source(1):